DOOR framework shows similar outcomes in skin infection trials - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

DOOR framework shows similar outcomes in skin infection trials

“Using DOOR can provide clinicians and patients with a better understanding of the benefits and risks of new anti-infectives being studied to treat skin infections.” 

  • By

  • Matthew Solan

  • August 24, 2026

  • 7 min

Share

  • 1

    Omadacycline and linezolid showed similar outcomes in a patient-centered analysis of 1,347 participants with acute bacterial skin infections.

  • 2

    The DOOR framework ranked outcomes based on survival and three undesirable events, allowing evaluation of treatment benefits and harms together.

  • 3

    About 80% of patients in both trials achieved the most desirable DOOR outcome, surviving without any prespecified undesirable events.

  • 4

    The probability of a more desirable outcome with omadacycline was 50.6% in OASIS-1 and 52.1% in OASIS-2, indicating no significant treatment differences.

  • 5

    The authors recommended future trials to incorporate DOOR and specific health-related quality-of-life instruments for better outcome distinction.

Original Source(s)

DOOR framework shows similar outcomes in skin infection trials

  • by Matthew Solan

  • August 24, 2026

Related Content

Framework Targets Hospital-Onset UTIs

The expert panel outlines surveillance, device management, and diagnostic stewardship strategies to address both catheter-associated and non–catheter-associated infections.

Immune imbalance markers: key factors in early recognition of multidrug-resistant bacterial infections in non-immunocompromised VAP patients

Omadacycline for Pediatric CAP

Case details intravenous-to-oral strategy after multiple antibiotic hypersensitivity reactions